New combination treatment against relapsed head and neck cancer

Posted by on June 6, 2018 9:02 pm
Categories: health

The five-year survival rate for locally-advanced head and neck cancer is only 46 percent, even with treatments including surgery, radiation, chemotherapy and/or genetically targeted treatments such as cetuximab. Often, the problem is that while treatments initially work, cancer evolves to resist treatment.

Leave a Reply

Your email address will not be published. Required fields are marked *